Deena buys ABBV 56.89: AbbVie Announces Initiation Of Pivotal Phase III Study Of Veliparib (ABT-888) In Patients With Advanced Breast Cancer
NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and ... ...
52 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home